Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.

Yasuharu Nakashima, Masakazu Kondo, Hiroshi Harada, Takahiko Horiuchi, Takashi Ishinishi, Hiroshi Jojima, Koji Kuroda, Hisaaki Miyahara, Ryuji Nagamine, Hitoshi Nakashima, Takeshi Otsuka, Isao Saikawa, Eisuke Shono, Eiichi Suematsu, Tomomi Tsuru, Ken Wada, Yukihide Iwamoto

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

We retrospectively observed the clinical efficacy and safety of tocilizumab (TCZ) in 74 patients with rheumatoid arthritis (RA) at 13 hospitals, without any restrictions on disease duration or stage, treatment history, and other influencing factors. TCZ was infused by the approved method, and disease activity was evaluated every 4 weeks until week 24 using a joint disease activity score (DAS28). Remission and treatment response were categorised using European League Against Rheumatism (EULAR) definitions. We also analysed the impact of previous treatment with other biologics and of concomitant methotrexate (MTX) therapy on the efficacy of TCZ. At week 24, the DAS28 had improved from 5.5 to 2.7 and the EULAR remission rate was 55.2%. Good and moderate responses according to the EULAR criteria were obtained in 61 and 36% of the patients, respectively. The biologic-naïve group had a significantly better DAS28 (2.1 vs. 2.8) and a significantly higher "good" response rate (86% vs. 54%) than the biologic-exposed group. Although the TCZ + MTX treatment group and the TCZ monotherapy group had a good response rate of 71 and 48%, respectively, the difference was not significant. Based on these results, we conclude that TCZ is able to significantly alleviate disease symptoms in a wide range of patients with RA in a normal clinical context.

Original languageEnglish
Pages (from-to)343-352
Number of pages10
JournalModern rheumatology / the Japan Rheumatism Association
Volume20
Issue number4
DOIs
Publication statusPublished - Aug 1 2010

Fingerprint

Biological Products
Methotrexate
Rheumatoid Arthritis
Rheumatic Diseases
Therapeutics
Joint Diseases
tocilizumab
History
Safety

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics : tocilizumab in combination with methotrexate. / Nakashima, Yasuharu; Kondo, Masakazu; Harada, Hiroshi; Horiuchi, Takahiko; Ishinishi, Takashi; Jojima, Hiroshi; Kuroda, Koji; Miyahara, Hisaaki; Nagamine, Ryuji; Nakashima, Hitoshi; Otsuka, Takeshi; Saikawa, Isao; Shono, Eisuke; Suematsu, Eiichi; Tsuru, Tomomi; Wada, Ken; Iwamoto, Yukihide.

In: Modern rheumatology / the Japan Rheumatism Association, Vol. 20, No. 4, 01.08.2010, p. 343-352.

Research output: Contribution to journalArticle

Nakashima, Y, Kondo, M, Harada, H, Horiuchi, T, Ishinishi, T, Jojima, H, Kuroda, K, Miyahara, H, Nagamine, R, Nakashima, H, Otsuka, T, Saikawa, I, Shono, E, Suematsu, E, Tsuru, T, Wada, K & Iwamoto, Y 2010, 'Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.', Modern rheumatology / the Japan Rheumatism Association, vol. 20, no. 4, pp. 343-352. https://doi.org/10.1007/s10165-010-0290-x
Nakashima, Yasuharu ; Kondo, Masakazu ; Harada, Hiroshi ; Horiuchi, Takahiko ; Ishinishi, Takashi ; Jojima, Hiroshi ; Kuroda, Koji ; Miyahara, Hisaaki ; Nagamine, Ryuji ; Nakashima, Hitoshi ; Otsuka, Takeshi ; Saikawa, Isao ; Shono, Eisuke ; Suematsu, Eiichi ; Tsuru, Tomomi ; Wada, Ken ; Iwamoto, Yukihide. / Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics : tocilizumab in combination with methotrexate. In: Modern rheumatology / the Japan Rheumatism Association. 2010 ; Vol. 20, No. 4. pp. 343-352.
@article{ed82d67a871a460b80ea07ae8abb425d,
title = "Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate.",
abstract = "We retrospectively observed the clinical efficacy and safety of tocilizumab (TCZ) in 74 patients with rheumatoid arthritis (RA) at 13 hospitals, without any restrictions on disease duration or stage, treatment history, and other influencing factors. TCZ was infused by the approved method, and disease activity was evaluated every 4 weeks until week 24 using a joint disease activity score (DAS28). Remission and treatment response were categorised using European League Against Rheumatism (EULAR) definitions. We also analysed the impact of previous treatment with other biologics and of concomitant methotrexate (MTX) therapy on the efficacy of TCZ. At week 24, the DAS28 had improved from 5.5 to 2.7 and the EULAR remission rate was 55.2{\%}. Good and moderate responses according to the EULAR criteria were obtained in 61 and 36{\%} of the patients, respectively. The biologic-na{\"i}ve group had a significantly better DAS28 (2.1 vs. 2.8) and a significantly higher {"}good{"} response rate (86{\%} vs. 54{\%}) than the biologic-exposed group. Although the TCZ + MTX treatment group and the TCZ monotherapy group had a good response rate of 71 and 48{\%}, respectively, the difference was not significant. Based on these results, we conclude that TCZ is able to significantly alleviate disease symptoms in a wide range of patients with RA in a normal clinical context.",
author = "Yasuharu Nakashima and Masakazu Kondo and Hiroshi Harada and Takahiko Horiuchi and Takashi Ishinishi and Hiroshi Jojima and Koji Kuroda and Hisaaki Miyahara and Ryuji Nagamine and Hitoshi Nakashima and Takeshi Otsuka and Isao Saikawa and Eisuke Shono and Eiichi Suematsu and Tomomi Tsuru and Ken Wada and Yukihide Iwamoto",
year = "2010",
month = "8",
day = "1",
doi = "10.1007/s10165-010-0290-x",
language = "English",
volume = "20",
pages = "343--352",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics

T2 - tocilizumab in combination with methotrexate.

AU - Nakashima, Yasuharu

AU - Kondo, Masakazu

AU - Harada, Hiroshi

AU - Horiuchi, Takahiko

AU - Ishinishi, Takashi

AU - Jojima, Hiroshi

AU - Kuroda, Koji

AU - Miyahara, Hisaaki

AU - Nagamine, Ryuji

AU - Nakashima, Hitoshi

AU - Otsuka, Takeshi

AU - Saikawa, Isao

AU - Shono, Eisuke

AU - Suematsu, Eiichi

AU - Tsuru, Tomomi

AU - Wada, Ken

AU - Iwamoto, Yukihide

PY - 2010/8/1

Y1 - 2010/8/1

N2 - We retrospectively observed the clinical efficacy and safety of tocilizumab (TCZ) in 74 patients with rheumatoid arthritis (RA) at 13 hospitals, without any restrictions on disease duration or stage, treatment history, and other influencing factors. TCZ was infused by the approved method, and disease activity was evaluated every 4 weeks until week 24 using a joint disease activity score (DAS28). Remission and treatment response were categorised using European League Against Rheumatism (EULAR) definitions. We also analysed the impact of previous treatment with other biologics and of concomitant methotrexate (MTX) therapy on the efficacy of TCZ. At week 24, the DAS28 had improved from 5.5 to 2.7 and the EULAR remission rate was 55.2%. Good and moderate responses according to the EULAR criteria were obtained in 61 and 36% of the patients, respectively. The biologic-naïve group had a significantly better DAS28 (2.1 vs. 2.8) and a significantly higher "good" response rate (86% vs. 54%) than the biologic-exposed group. Although the TCZ + MTX treatment group and the TCZ monotherapy group had a good response rate of 71 and 48%, respectively, the difference was not significant. Based on these results, we conclude that TCZ is able to significantly alleviate disease symptoms in a wide range of patients with RA in a normal clinical context.

AB - We retrospectively observed the clinical efficacy and safety of tocilizumab (TCZ) in 74 patients with rheumatoid arthritis (RA) at 13 hospitals, without any restrictions on disease duration or stage, treatment history, and other influencing factors. TCZ was infused by the approved method, and disease activity was evaluated every 4 weeks until week 24 using a joint disease activity score (DAS28). Remission and treatment response were categorised using European League Against Rheumatism (EULAR) definitions. We also analysed the impact of previous treatment with other biologics and of concomitant methotrexate (MTX) therapy on the efficacy of TCZ. At week 24, the DAS28 had improved from 5.5 to 2.7 and the EULAR remission rate was 55.2%. Good and moderate responses according to the EULAR criteria were obtained in 61 and 36% of the patients, respectively. The biologic-naïve group had a significantly better DAS28 (2.1 vs. 2.8) and a significantly higher "good" response rate (86% vs. 54%) than the biologic-exposed group. Although the TCZ + MTX treatment group and the TCZ monotherapy group had a good response rate of 71 and 48%, respectively, the difference was not significant. Based on these results, we conclude that TCZ is able to significantly alleviate disease symptoms in a wide range of patients with RA in a normal clinical context.

UR - http://www.scopus.com/inward/record.url?scp=78349285989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78349285989&partnerID=8YFLogxK

U2 - 10.1007/s10165-010-0290-x

DO - 10.1007/s10165-010-0290-x

M3 - Article

C2 - 20480201

AN - SCOPUS:78349285989

VL - 20

SP - 343

EP - 352

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 4

ER -